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Abstract
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The Gleason scoring system is a main component of a prostate cancer diagnosis. It also serves as a
risk communication tool that facilitates shared treatment decision making. However, the system is
highly complex and therefore difficult to communicate; factors which have been shown to
undermine well-informed and high-quality shared treatment decision making. To systematically
explore prostate cancer patients understanding of the Gleason scoring system (GSS), we assessed
knowledge and perceived importance among men who had completed treatment (N = 50). Patients
were administered a cross-sectional survey that assessed patient knowledge and patients’ perceived
importance of the GSS, as well as demographics, medical factors (e.g., Gleason score at
diagnosis), and health literacy. Bivariate analyses were conducted to identify associations with
patient knowledge and perceived importance of the GSS. The sample was generally well-educated
(48% with a bachelor’s degree or higher), and health literate (M = 12.9, SD = 2.2, range = 3–15).
Despite this, fewer than 50% had adequate knowledge of the GSS. Patients’ perceived
understanding of the importance of the GSS was moderate (M = 2.8, SD = 1.0, range = 0–4) and
was significantly associated with GSS knowledge (p < .01). Additionally, GSS knowledge was
negatively associated with years since biopsy (p < .05). Age and health literacy were positively
associated with patients’ perceived importance of the GSS (ps < .05), but not with GSS
knowledge. Patient knowledge is thus less than optimal and could benefit from enhanced
communication to maximize shared treatment decision making. Future studies are needed to
explore the potential utility of a simplified Gleason grading system.
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Introduction
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Prostate cancer patients typically have challenging decisions to make regarding their
treatment options and are encouraged to engage in shared decision making with their
providers [1]. One component of the decision making process is a patients’ Gleason score,
which is intended to facilitate risk communication and enhance quality treatment decision
making [2]. The Gleason scoring system (GSS) is based on objectification of glandular dedifferentiation [3]. The system quantifies a primary and secondary histologic pattern (each
graded 1 through 5; grades 1 and 2 are classified as benign lesions) and the two patterns are
summed together and reported as the Gleason sum (e.g., 3+3=6, 4+3=7). Gleason sums 6
and 7 are globally considered as low and intermediate risk, respectively, while Gleason sums
8 or higher are regarded as high risk [4]. The GSS has undergone several revisions [5, 6],
resulting in a more concordant reporting system between pathologic findings on biopsy and
final pathologic specimens [7].
Patient-provider communication is vital to patients’ comprehension of their disease, as well
as their long-term quality of life [8]. However, providers struggle to effectively communicate
the significance of the GSS to prostate cancer patients, creating barriers for quality patient
treatment decision making [9]. Patient interviews suggest prostate cancer patients are
confused and uncertain as to how to apply their Gleason score to clinical decisions [9].
Barriers to effective comprehension likely stem, in large part, from unnecessary complexities
within the GSS (e.g., Gleason score less than 6 is considered benign) [9]. As such, it is
important to quantify patient deficits in their understanding of the GSS in order to identify
teachable moments for both streamlining provider communication and improvements in
patient comprehension.
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To systematically explore patient understanding, we conducted a quantitative survey of
prostate cancer patients who had completed treatment to assess (a) patients’ knowledge of
the GSS; (b) patients’ perceived importance of the GSS; and (c) the relationship between
demographic, medical factors, and health literacy with GSS knowledge and perceived
importance.

Materials and Methods
Participants and procedure

Author Manuscript

Attending urologic oncology providers at Fox Chase Cancer Center (FCCC) recruited
prostate cancer patients during a routine clinic visit post-treatment. Patients were eligible if
they were between the ages of 40 and 80, had been diagnosed with prostate cancer at FCCC
or an outside institution and referred to FCCC for care, able to communicate in English, and
be competent to consent. After providing written consent, eligible patients completed a print
questionnaire that took approximately 15 minutes to complete. Patients unable to complete
the questionnaire while at the clinic were able to complete the questionnaire at home and
were provided a pre-addressed and stamped envelope. The FCCC Institutional Review
Board approved this study.
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Measures
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Demographic and background variables—Demographic variables were assessed via
self-report on the questionnaire and included age, race/ethnicity, marital status, and
education. Medical background variables were abstracted from patients’ charts and included
biopsy date, Gleason score at diagnosis, PSA score at diagnosis, stage of cancer at diagnosis,
and treatment type. Anxiety was assessed using the Memorial Anxiety Scale for Prostate
Cancer subscales: general prostate cancer anxiety (11 items), PSA anxiety (3 items), and
fear of recurrence anxiety (4 items). Each item was scored on a 4-point Likert-type scale and
were recoded to indicated clinically significant anxiety by multiplying each scale score by
1.5 [10]. Health literacy was assessed using a validated 3-item scale measured on a 5-point
Likert-type scale [11]. The three items were summed to create a total score with greater
scores indicating greater health literacy.
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Gleason scoring system knowledge and perceived importance—GSS knowledge
was scored using an author-constructed 4-item scale assessing patient knowledge about the
2005 ISUP Gleason scoring system [6]. Sample items include “Which cancer is more
aggressive: 4 + 3 = 7, 3 + 4 = 7, or are both are the same?” and “Gleason Score 4+4=8 is
considered: low, intermediate, or high risk?” Each item was recoded to correct (1) or
incorrect (0) and a total score was calculated with a maximum score of 4. The scale
demonstrated acceptable reliability (α = .72). Patients’ perceived importance of the GSS was
assessed using an author-constructed 5-item scale. Items were scored on a 5-point Likert
type scale and a mean scale score was calculated. Sample items include “My doctor’s
explanation of the Gleason system made sense to me” and “My understanding of my
Gleason score has significantly impacted my treatment decision.” The scale demonstrated
acceptable reliability (α = .79).
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Data analyses
Descriptive statistics (e.g., frequencies, means) were calculated for all variables using SPSS
version 24.0 (SPSS, Inc., Chicago, IL). Variables were assessed for normality using the
Shapiro-Wilk test. Bivariate associations were then tested between demographic and
background variables with GSS knowledge and perceived importance. Bivariate analyses
were completed using the Mann-Whitney U, Kruskal-Wallis, and Spearman’s rho tests.

Results

Author Manuscript

A total of 50 eligible patients completed the questionnaire. Patients had a mean age of 63.5
(SD = 7.5), were predominantly white (75.0%), married (86.0%), and 48.0% had a
bachelor’s degree or higher (Table 1). Additionally, patients had a relatively high mean
health literacy score of 12.9 (SD = 2.2), out of a possible maximum score of 15. The
majority of patients had a Stage II cancer diagnosis (74%) with a mean Gleason score of 7.0
(SD = 0.9) and a mean PSA score of 6.1 (SD = 3.4) at diagnosis. All patients were
undergoing follow-up with their treating urologic oncologist and were a mean 3.6 years (SD
= 3.2) from the date of their prostate cancer diagnosis. Of note, 3 patients (6%) have
clinically significant PSA anxiety, 22% have general prostate anxiety and 86% have
clinically significant fear of recurrence. Patients had strikingly low knowledge of the GSS,
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with a mean score of 1.8 out of a possible 4.0 (SD = 1.4). Only 32.0% of patients scored
greater than 50.0% on the GSS knowledge scale. Similarly, the mean scale score of patient
perceived importance of the GSS was moderately low (M = 2.8, SD = 1.0, range = 0–4).
Significant bivariate associations were found with GSS knowledge and perceived importance
(Table 2). GSS knowledge and patient perceptions of GSS were significantly associated
[rs(48) = .488, p < .01]. Health literacy was significantly associated with patient perceived
importance of the GSS [rs(48) = .399, p < .01], however health literacy was not significantly
associated with GSS knowledge [rs(48) = .190, p > .05]. Lastly, age was positively
associated with perceived importance of the GSS [rs(48) = .336, p < .05] and Gleason score
at diagnosis [rs(47) = .491, p < .01].

Discussion
Author Manuscript

While a patients’ Gleason score is a critical part of the decision making process for prostate
cancer treatment, many patients are confused about the meaning of their score [9]. Despite
revisions over the past 50 years, providers still struggle to describe and convey the meaning
of the GSS to patients [9]. Our study findings demonstrate that even among prostate cancer
patients undergoing routine post-treatment active monitoring, with high educational
attainment and health literacy, the majority have low knowledge about the GSS.
Additionally, patients expressed moderate perceived importance of the GSS. GSS knowledge
was positively associated with patients’ perceived importance of the GSS, suggesting that
individuals who have a better understanding of how their Gleason score is calculated have a
greater understanding of how important their Gleason score is when making treatment
decisions with their providers.
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Health literacy was positively related to perceived importance of the GSS, indicating that
patients who have greater capacity to understand health information are better able to
understand the importance of their Gleason score when making treatment decisions.
However, while health literacy was significantly associated with perceived importance, it
was not significantly related to GSS knowledge. Thus, even patients with high health literacy
have difficulty understanding the GSS. While providers are well-intentioned in their
communication interactions with patients, it is typically difficult to identify patients with low
health literacy [12]. Further, patients are often unwilling to disclose their limitations in
understanding health information [13]. Accurate assessment of patients’ grasp of disease
severity is especially critical in an era when efforts to enroll patients into active surveillance
protocols are crucial for minimizing prostate cancer overtreatment, but are hindered by
patient confusion [14].

Author Manuscript

Only one significant association was identified between perceived importance of the GSS
and background factors, notably age. Age was positively associated with perceived
importance of the GSS but was not significantly related to GSS knowledge. Despite low
GSS knowledge, older prostate cancer patients understand the importance of their Gleason
score in their treatment decision making. This relationship needs to be further investigated to
understand the relationship between age and perceptions of the GSS. Age was also
associated with patients’ Gleason score at diagnosis, which is consistent with previous
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research [15]. There were no significant associations between knowledge and background
factors. Further, while not significantly associated with knowledge or perceived importance
of the GSS, 43 patients (86%) have clinically significant fear of cancer recurrence in spite of
the fact they received adequate treatment.
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Limitations include the small sample size and retrospective study design. However, the study
findings suggest that even patients who have years of experience managing prostate cancer
diagnoses are still confused about the GSS. Additionally, the study was conducted with a
patient population at a comprehensive cancer center, limiting its generalizability to other
clinical settings. Further, the patient population is fairly well educated and has low diversity
in terms of racial/ethnic groups. Future research should assess a larger, more diverse patient
population over time to assess changes in patient understanding and its relationship with
treatment decision making. Lastly, the GSS was not examined alongside other decision
making factors (see [16]) that may impact treatment decision making. Further research is
needed to examine how the GSS and other decision making factors interact and impact
shared treatment decision making for prostate cancer.
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To help simplify the GSS and reduce confusion and fear for patients [17], recent revisions to
the system were proposed and accepted at the 2014 ISUP Consensus Conference [18] and
accepted by the World Health Organization in 2016 [19]. The revisions not only updated the
grading of Gleason patterns (e.g., regardless of morphology, all cribriform glands are
assigned a Gleason pattern 4), but also revised the prognostic scoring system by dividing it
into a five-grade group system [18]. The new five-grade group system may help increase
clarity for patients and providers [20]. Despite adoption by the ISUP [18] and WHO [19],
and the potential for reduced confusion in treatment decision making [20], the new fivegrade group system has yet to enjoy wide-spread adoption. Future work is needed to
determine if this new system results in better patient comprehension and understanding, and
how this simplified system, in turn, impacts treatment decision making.
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Currently, many urologists explain to patients the prognostic implications of their Gleason
score similar to what is adopted in the new system. In the present study, most patients
understood the importance of the GSS in the treatment decision making process, but the
majority of patients were still confused about their Gleason score. As patients are
increasingly encouraged to participate in shared decision making with their providers [1],
the study findings underscore the importance in providers clearly communicating to the
patient how their Gleason score is calculated and what that score indicates. To effectively
convey the GSS to their patients, providers should be sensitized to communication skills that
enhance prostate cancer patients’ understanding of vital health information [21]. Providers
who are attentive to these issues initiate more patient-centered communication that can help
facilitate patients’ understanding of critical health information [22]. While decision aids
have shown promise in facilitating treatment decision making [23], few have incorporated
the GSS. Existing decision aids that have incorporated the GSS have not yet been tested for
efficacy [24, 25]. The findings presented here dovetail with the need for a new system;
however, further validation studies are needed to determine if the new system is able to
deliver more comprehensible patient information, streamlines the communication process
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between providers and patients, and ultimately results in higher quality decision making and
care.
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Patient characteristics (N=50)
Variable

N (%) or M (SD)

Age

63.5 (7.5)

Race/ethnicity
White

37 (74.0)

a

13 (26.0)

Other

Marital status
Married

43 (86.0)

Other

7 (14.0)

Education

Author Manuscript

High school diploma

14 (28.0)

Some college

12 (24.0)

Bachelor’s degree

16 (32.0)

Graduate degree

8 (16.0)

Years since date of biopsy

b

3.6 (3.2)

b

7.0 (0.9)

Gleason score at diagnosis

c

6.1 (3.4)

PSA score at diagnosis

Stage of cancer at diagnosis

d

Stage I

5 (10.4)

Stage II

36 (75.0)

Stage III

7 (14.6)

Treatment type

Author Manuscript

Prostatectomy

42 (84.0)

Radiation

4 (8.0)

Prostatectomy + radiation

2 (4.0)

Active surveillance

2 (4.0)

General prostate cancer anxiety
Yes

11 (22.0)

No

39 (78.0)

PSA anxiety
Yes

3 (6.0)

No

47 (94.0)

Fear of recurrence

Author Manuscript

Yes

43 (86.0)

No

7 (14.0)

Health literacy (max score = 15)

12.9 (2.2)

GSS knowledge (max score = 4)

1.8 (1.4)

Perceived importance of the GSS (mean scale score)

2.8 (1.0)

Note: PSA = Prostate Specific Antigen. GSS = Gleason scoring system.
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Racial/ethnic groups (Non-Hispanic Black=10, Asian=2, Hispanic = 1) collapsed into “other” due to low sample size

b

N=49

c
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N=43

d

N=48
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Table 2.
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Correlations of prostate cancer patients’ knowledge and perceptions of the Gleason Scoring System
1
1. Age

2

3

4

5

–

**

2. Gleason score

.491

–

3. Health literacy

.218

.142

–

4. GSS knowledge

−.055

.040

.190

*

.218

5. Perceived importance of the GSS

.336

**

.399

–

**

.488

–

Note: Only variables with at least one significant association are shown. GSS = Gleason Scoring System
*

p < .05

**

p < .01
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